Evidence map›Paper›PMID 40610457›Full record

ArticleNature communications2025

Pancreatic β-cell regeneration in situ by the ALK3 agonist THR-123.

Silvia Álvarez-Cubela, Isabella D Altilio, Mayur Doke, Dagmar Klein, Alejandro Tamayo, Óscar Alcázar, Carlos García Santana, Mirza Muhammad Fahd Qadir, Charles García Alver, Francis Cruz and 10 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Recent Updates on Diabetes and Bone.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Silvia Álvarez-CubelaDiabetes Research Institute, University of Miami Miller School of Medicine (UM-MSoM), Miami, FL, USA.
Isabella D Altilio *Diabetes Research Institute, University of Miami Miller School of Medicine (UM-MSoM), Miami, FL, USA.ORCID http://orcid.org/0000-0002-1153-1785
Mayur Doke *Diabetes Research Institute, University of Miami Miller School of Medicine (UM-MSoM), Miami, FL, USA.
Dagmar Klein *Diabetes Research Institute, University of Miami Miller School of Medicine (UM-MSoM), Miami, FL, USA.
Alejandro TamayoDepartment of Medicine, Division of Metabolism, Endocrinology and Diabetes, UM-MSoM, Miami, FL, USA.ORCID http://orcid.org/0000-0002-4801-8125
Óscar AlcázarDiabetes Research Institute, University of Miami Miller School of Medicine (UM-MSoM), Miami, FL, USA.
Carlos García SantanaDiabetes Research Institute, University of Miami Miller School of Medicine (UM-MSoM), Miami, FL, USA.
Mirza Muhammad Fahd QadirDiabetes Research Institute, University of Miami Miller School of Medicine (UM-MSoM), Miami, FL, USA.ORCID http://orcid.org/0000-0002-6764-6151
Charles García AlverDepartment of Biomedical Engineering, UM-MSoM, Miami, FL, USA.ORCID http://orcid.org/0000-0003-1195-454X
Francis CruzDiabetes Research Institute, University of Miami Miller School of Medicine (UM-MSoM), Miami, FL, USA.
Olivia BiggsDiabetes Research Institute, University of Miami Miller School of Medicine (UM-MSoM), Miami, FL, USA.
Jorge David Tovar CastroDiabetes Research Institute, University of Miami Miller School of Medicine (UM-MSoM), Miami, FL, USA.ORCID http://orcid.org/0000-0002-0810-4379
Belén Navarro-RubioUniversidad Francisco de Vitoria, Madrid, Spain.
Camillo RicordiDiabetes Research Institute, University of Miami Miller School of Medicine (UM-MSoM), Miami, FL, USA.
Alejandro CaicedoDepartment of Medicine, Division of Metabolism, Endocrinology and Diabetes, UM-MSoM, Miami, FL, USA.ORCID http://orcid.org/0000-0002-3765-3529
Peter BuchwaldDiabetes Research Institute, University of Miami Miller School of Medicine (UM-MSoM), Miami, FL, USA.ORCID http://orcid.org/0000-0003-2732-8180
Ashutosh AgarwalDepartment of Biomedical Engineering, UM-MSoM, Miami, FL, USA.
Elisa OltraEscuela de Doctorado, Universidad Católica de Valencia, Valencia, Spain.
Ricardo Luis PastoriDiabetes Research Institute, University of Miami Miller School of Medicine (UM-MSoM), Miami, FL, USA. rpastori@med.miami.edu.
Juan Domínguez-BendalaDiabetes Research Institute, University of Miami Miller School of Medicine (UM-MSoM), Miami, FL, USA. jdominguez2@med.miami.edu.ORCID http://orcid.org/0000-0001-9410-9143

Funding

BMP signaling and regenerative plasticity: Correlating dynamic scRNAseq and real-time anatomical remodeling in T1D pancreatic slicesR01DK138210 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Juan Dominguez-Bendala, RICARDO L PASTORI · 2024 to 2026
$1.6M
Single-cell longitudinal analysis of regeneration in human pancreatic slicesR01DK130846 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI DOMINGUEZ-BENDALA, JUAN, PASTORI, RICARDO L · 2021 to 2023
$1.2M
HIGH-RESOLUTION CHARACTERIZATION OF HUMAN DUCTAL PROGENITOR CELLS AND THEIR REGENERATION POTENTIALU01DK120393 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI DOMINGUEZ-BENDALA, JUAN, PASTORI, RICARDO L · 2018 to 2021
$921k
NIDDK NIH HHS R01 DK130846NIDDK NIH HHS R01 DK138210NIDDK NIH HHS U01 DK120393
6 · The paper itself

Abstract

The demonstration that BMP signaling activates progenitor-like populations within pancreatic ducts supports the potential use of BMP receptor agonists to induce islet neogenesis in situ. In this context, we tested the ability of THR-123, a cyclic peptide with BMP-7-like activity, to regenerate β-cell mass in diabetic mice. We show here that treatment with THR-123 reduces hyperglycemia through the rapid formation of new BrdU-labeled islets, many in apposition to ducts. These islets, unlike those from non-diabetic controls, feature an extensive intrainsular network of ductal tissue. The earlier stages of THR-123-induced β-cell formation were reproduced in live pancreatic slices, an organotypic model that allowed us to visualize ductal cells transitioning to glucose-responsive insulin-expressing cells in real time. scRNAseq analyses further suggest that this transition occurs through a hybrid ducto-acinar stage similar to that previously reported in humans. Taken together, our data support the conclusion that these islets arise predominantly by neogenesis. These results pave the way for the design of pharmacological strategies to treat insulin-dependent diabetes.

Indexed as

Bone Morphogenetic Protein Receptors, Type IInsulin-Secreting CellsRegenerationAnimalsDiabetes Mellitus, ExperimentalInsulinIslets of LangerhansMaleMiceMice, Inbred C57BLPancreatic DuctsSignal TransductionBmpr1a protein, mouseBone Morphogenetic Protein Receptors, Type IInsulin

Identifiers

PMID40610457
PMCPMC12226732

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.